Literature DB >> 27192564

CD28 Costimulation: From Mechanism to Therapy.

Jonathan H Esensten1, Ynes A Helou2, Gaurav Chopra3, Arthur Weiss4, Jeffrey A Bluestone5.   

Abstract

Ligation of the CD28 receptor on T cells provides a critical second signal alongside T cell receptor (TCR) ligation for naive T cell activation. Here, we discuss the expression, structure, and biochemistry of CD28 and its ligands. CD28 signals play a key role in many T cell processes, including cytoskeletal remodeling, production of cytokines, survival, and differentiation. CD28 ligation leads to unique epigenetic, transcriptional, and post-translational changes in T cells that cannot be recapitulated by TCR ligation alone. We discuss the function of CD28 and its ligands in both effector and regulatory T cells. CD28 is critical for regulatory T cell survival and the maintenance of immune homeostasis. We outline the roles that CD28 and its family members play in human disease and we review the clinical efficacy of drugs that block CD28 ligands. Despite the centrality of CD28 and its family members and ligands to immune function, many aspects of CD28 biology remain unclear. Translation of a basic understanding of CD28 function into immunomodulatory therapeutics has been uneven, with both successes and failures. Such real-world results might stem from multiple factors, including complex receptor-ligand interactions among CD28 family members, differences between the mouse and human CD28 families, and cell-type specific roles of CD28 family members.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27192564      PMCID: PMC4932896          DOI: 10.1016/j.immuni.2016.04.020

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  203 in total

Review 1.  CD28-mediated co-stimulation: a quantitative support for TCR signalling.

Authors:  Oreste Acuto; Frédérique Michel
Journal:  Nat Rev Immunol       Date:  2003-12       Impact factor: 53.106

2.  c-Rel is required for chromatin remodeling across the IL-2 gene promoter.

Authors:  Sudha Rao; Steve Gerondakis; Donna Woltring; M Frances Shannon
Journal:  J Immunol       Date:  2003-04-01       Impact factor: 5.422

Review 3.  An enigmatic tail of CD28 signaling.

Authors:  Jonathan S Boomer; Jonathan M Green
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-06-09       Impact factor: 10.005

4.  Grb2 and Gads exhibit different interactions with CD28 and play distinct roles in CD28-mediated costimulation.

Authors:  Ryosuke Watanabe; Yohsuke Harada; Kei Takeda; Jun Takahashi; Kazunobu Ohnuki; Shuhei Ogawa; Daisuke Ohgai; Nanako Kaibara; Osamu Koiwai; Kazunari Tanabe; Hiroshi Toma; Kazuo Sugamura; Ryo Abe
Journal:  J Immunol       Date:  2006-07-15       Impact factor: 5.422

Review 5.  Protein arginine methylation in lymphocyte signaling.

Authors:  Fabien Blanchet; Brandon T Schurter; Oreste Acuto
Journal:  Curr Opin Immunol       Date:  2006-04-17       Impact factor: 7.486

6.  CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines.

Authors:  C B Thompson; T Lindsten; J A Ledbetter; S L Kunkel; H A Young; S G Emerson; J M Leiden; C H June
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

7.  Loss of CD28 expression on CD8(+) T cells is induced by IL-2 receptor gamma chain signalling cytokines and type I IFN, and increases susceptibility to activation-induced apoptosis.

Authors:  N J Borthwick; M Lowdell; M Salmon; A N Akbar
Journal:  Int Immunol       Date:  2000-07       Impact factor: 4.823

8.  Failure to upregulate cell surface PD-1 is associated with dysregulated stimulation of T cells by TGN1412-like CD28 superagonist.

Authors:  Thilipan Thaventhiran; Naif Alhumeed; Han X A Yeang; Swaminathan Sethu; Jocelyn S Downey; Ahmad F Alghanem; Adedamola Olayanju; Emma L Smith; Michael J Cross; Steven D Webb; Dominic P Williams; Adrian Bristow; Christina Ball; Richard Stebbings; Jean G Sathish
Journal:  MAbs       Date:  2014-10-30       Impact factor: 5.857

9.  Inhibition of the kinase Csk in thymocytes reveals a requirement for actin remodeling in the initiation of full TCR signaling.

Authors:  Ying Xim Tan; Boryana N Manz; Tanya S Freedman; Chao Zhang; Kevan M Shokat; Arthur Weiss
Journal:  Nat Immunol       Date:  2013-12-08       Impact factor: 25.606

10.  Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects.

Authors:  S Alice Long; Karen Cerosaletti; Paul L Bollyky; Megan Tatum; Heather Shilling; Sheng Zhang; Zhong-Yin Zhang; Catherine Pihoker; Srinath Sanda; Carla Greenbaum; Jane H Buckner
Journal:  Diabetes       Date:  2009-10-29       Impact factor: 9.461

View more
  218 in total

1.  Use of Polymeric Nanoparticle Platform Targeting the Liver To Induce Treg-Mediated Antigen-Specific Immune Tolerance in a Pulmonary Allergen Sensitization Model.

Authors:  Qi Liu; Xiang Wang; Xiangsheng Liu; Sanjan Kumar; Grant Gochman; Ying Ji; Yu-Pei Liao; Chong Hyun Chang; Wesley Situ; Jianqin Lu; Jinhong Jiang; Kuo-Ching Mei; Huan Meng; Tian Xia; Andre E Nel
Journal:  ACS Nano       Date:  2019-04-12       Impact factor: 15.881

2.  Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases.

Authors:  Max A Cheng; Emily Farmer; Claire Huang; John Lin; Chien-Fu Hung; T-C Wu
Journal:  Hum Gene Ther       Date:  2018-03-16       Impact factor: 5.695

3.  Considering B7-CD28 as a family through sequence and structure.

Authors:  Sean M West; Xiaodi A Deng
Journal:  Exp Biol Med (Maywood)       Date:  2019-06-17

Review 4.  An update on lupus animal models.

Authors:  Wei Li; Anton A Titov; Laurence Morel
Journal:  Curr Opin Rheumatol       Date:  2017-09       Impact factor: 5.006

5.  A selective CD28 antagonist and rapamycin synergise to protect against spontaneous autoimmune diabetes in NOD mice.

Authors:  Alix Besançon; Tania Goncalves; Fabrice Valette; Caroline Mary; Bernard Vanhove; Lucienne Chatenoud; Sylvaine You
Journal:  Diabetologia       Date:  2018-05-29       Impact factor: 10.122

6.  Increased Pretransplant Frequency of CD28+ CD4+ TEM Predicts Belatacept-Resistant Rejection in Human Renal Transplant Recipients.

Authors:  M Cortes-Cerisuelo; S J Laurie; D V Mathews; P D Winterberg; C P Larsen; A B Adams; M L Ford
Journal:  Am J Transplant       Date:  2017-06-30       Impact factor: 8.086

7.  T-cell Homing Therapy for Reducing Regulatory T Cells and Preserving Effector T-cell Function in Large Solid Tumors.

Authors:  Jiemiao Hu; Chuang Sun; Chantale Bernatchez; Xueqing Xia; Patrick Hwu; Gianpietro Dotti; Shulin Li
Journal:  Clin Cancer Res       Date:  2018-02-01       Impact factor: 12.531

Review 8.  Tolerance in the Age of Immunotherapy.

Authors:  Jeffrey A Bluestone; Mark Anderson
Journal:  N Engl J Med       Date:  2020-09-17       Impact factor: 91.245

Review 9.  The promise and challenges of immune agonist antibody development in cancer.

Authors:  Patrick A Mayes; Kenneth W Hance; Axel Hoos
Journal:  Nat Rev Drug Discov       Date:  2018-06-15       Impact factor: 84.694

Review 10.  Tim-3, Lag-3, and TIGIT.

Authors:  Nicole Joller; Vijay K Kuchroo
Journal:  Curr Top Microbiol Immunol       Date:  2017       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.